BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Invirase saquinavir regulatory update

CHMP began a review of the risk/benefit profile of Roche's HIV drug Invirase saquinavir after a QT study in healthy volunteers suggested the Invirase boosted by Norvir ritonavir caused...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >